New Study: Belarus Pharmaceuticals & Healthcare Report Q4 2015

Belarus continues to present limited opportunities for drugmakers owing to the heightened economic risk in the country. Regional security risks, namely between Russia and the west, poor governance and heavy state presence in the economy will present considerable barriers to foreign interest .

Headline Expenditure Projections

Pharmaceuticals: BYR10,405bn in 2014 (USD1.02bn) to BYR12,769bn (USD863mn) in 2015; +22.7% in local currency terms and -15.0% in US dollar terms.
Healthcare: BYR48,816bn (USD4.76bn) in 2014 to BYR62,047bn (USD4.19bn) in 2015; +27.1% in local currency terms and -12.0% in US dollar terms.

Risk/Reward Index

Belarus has a Risk Reward Index (RRI) score of 45.1, below the regional average of 49.3, making it the 15th most attractive market in the Central and Eastern European region. Belarus scores well below the regional average for Risks on account of its economic instability and unfavourable pharmaceutical regulatory environment. These factors are key contributors to its low standing in our index.

Full Report Details at
- http://www.fastmr.com/prod/1047914_belarus_pharmaceuticals.aspx?afid=301

Key Trends And Developments

Cuban-manufactured drugs have been sold in the Belarusian healthcare system thanks to the mutual recognition of drug registrations and a compensatory exchange agreement between the countries, according to the ambassador of Belarus in Cuba, speaking in July 2015. Several biotechnology products from Cuba, including Heberprot-P used for the healing of diabetic foot ulcers, are already being used in Minsk according to the ambassador.

The Belarus Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belarus Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belarus pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Belarus, to test other views - a key input for successful budgeting and strategic business planning in the Belarusian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Belarusian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Belarus.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015